Pub Date : 2021-02-10DOI: 10.17650/1726-9776-2020-16-4-82-88
A. Musaelyan, V. Nazarov, S. Lapin, O. Pavlova, D. Viktorov, А. N. Toropovsky, A. G. Boriskin, S. Reva, S. Petrov
Background. Prostate cancer holds one of the leading positions among malignant neoplasms in men. One of the most well-studied tumor-specific maskers is the PCA3 score in urine obtained after prostate massage. However, the study of the PCA3 score without prostate massage can significantly simplify the preanalytical phase of the study and minimize discomfort for the patient. Objective . Investigation of the diagnostic significance of PCA3, determined in urine sediment without prostate massage and its comparison with the PCA3 score after prostate massage. Materials and methods . The study included 2 groups of patients. In the first group (n = 50), the PCA3 score was assessed without prostate massage, and in the second group (n = 15) PCA3 was assessed in urine obtained before and after massage. Results. The area under the ROC-curve (AUC) for the PCA3 score without prostate massage was 0.722 (95 % confidence interval 0.579—0.865; p = 0.008). Using the ROC analysis, the threshold value, sensitivity and specificity were determined: 25, 72.41 % (95 % confidence interval 54.28— 85.30 %) and 57.14 % (95 % confidence interval 36.55—75.53 %), respectively. The PCA3 score after massage was found to be more sensitive than without prostate massage. A small volume of material, less than 20 ml, significantly affects the sensitivity of PCA3 without massage. Conclusion . PCA3 without prostate massage may serve as an option to improve the early diagnosis of prostate cancer, but its advantage over PCA3 after prostate massage has not been shown.
{"title":"Possibility of using PCA3 score without prostate massage in urine for diagnosing prostate cancer","authors":"A. Musaelyan, V. Nazarov, S. Lapin, O. Pavlova, D. Viktorov, А. N. Toropovsky, A. G. Boriskin, S. Reva, S. Petrov","doi":"10.17650/1726-9776-2020-16-4-82-88","DOIUrl":"https://doi.org/10.17650/1726-9776-2020-16-4-82-88","url":null,"abstract":"Background. Prostate cancer holds one of the leading positions among malignant neoplasms in men. One of the most well-studied tumor-specific maskers is the PCA3 score in urine obtained after prostate massage. However, the study of the PCA3 score without prostate massage can significantly simplify the preanalytical phase of the study and minimize discomfort for the patient. Objective . Investigation of the diagnostic significance of PCA3, determined in urine sediment without prostate massage and its comparison with the PCA3 score after prostate massage. Materials and methods . The study included 2 groups of patients. In the first group (n = 50), the PCA3 score was assessed without prostate massage, and in the second group (n = 15) PCA3 was assessed in urine obtained before and after massage. Results. The area under the ROC-curve (AUC) for the PCA3 score without prostate massage was 0.722 (95 % confidence interval 0.579—0.865; p = 0.008). Using the ROC analysis, the threshold value, sensitivity and specificity were determined: 25, 72.41 % (95 % confidence interval 54.28— 85.30 %) and 57.14 % (95 % confidence interval 36.55—75.53 %), respectively. The PCA3 score after massage was found to be more sensitive than without prostate massage. A small volume of material, less than 20 ml, significantly affects the sensitivity of PCA3 without massage. Conclusion . PCA3 without prostate massage may serve as an option to improve the early diagnosis of prostate cancer, but its advantage over PCA3 after prostate massage has not been shown.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67764299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-10DOI: 10.17650/1726-9776-2020-16-4-215-219
O. Mailyan, M. Golovashchenko, K. Y. Kanukoev, V. Surkova, V. A. Burakova, N. Vorobyev, A. Krasheninnikov, A. Kalpinskiy, B. Alekseev, A. Kaprin
The incidence of mesenchymal bladder tumors is 1–5 %; of them, 0.43 % are bladder leiomyomas. The choice of treatment strategy primar-ily depends on the size and location of the tumor. Small endovesical leiomyomas can be removed by transurethral resection of the bladder, while in case of large (>5 cm) intramural or extravesical leiomyomas, laparoscopic resection is more effective. In this article, we report a case of large (>7 cm) bladder leiomyoma in a 28-year-old female patient. The patient has undergone laparoscopic resection of the bladder at P.A. Herzen Moscow Oncology Research Institute.
{"title":"Large bladder leiomyoma: a case report","authors":"O. Mailyan, M. Golovashchenko, K. Y. Kanukoev, V. Surkova, V. A. Burakova, N. Vorobyev, A. Krasheninnikov, A. Kalpinskiy, B. Alekseev, A. Kaprin","doi":"10.17650/1726-9776-2020-16-4-215-219","DOIUrl":"https://doi.org/10.17650/1726-9776-2020-16-4-215-219","url":null,"abstract":"The incidence of mesenchymal bladder tumors is 1–5 %; of them, 0.43 % are bladder leiomyomas. The choice of treatment strategy primar-ily depends on the size and location of the tumor. Small endovesical leiomyomas can be removed by transurethral resection of the bladder, while in case of large (>5 cm) intramural or extravesical leiomyomas, laparoscopic resection is more effective. In this article, we report a case of large (>7 cm) bladder leiomyoma in a 28-year-old female patient. The patient has undergone laparoscopic resection of the bladder at P.A. Herzen Moscow Oncology Research Institute.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67763410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-10DOI: 10.17650/1726-9776-2020-16-4-89-97
A. A. Kopylov, V. Gorelov, N. Margaryants, S. Gorelov
Background . Prostate cancer (PCa) is one of the most common malignancies. The gold standard of PCa diagnostics is morphological examination of prostate tissues obtained using 10-12-core biopsy. However, the number of false-negative results and detected clinically insignificant forms of cancer remain high. Magnetic resonance imaging (MRI) is the most sensitive and specific method of radiation diagnosis of PCa. The use of MRI data for prostate biopsy (fusion-biopsy) increases the accuracy of this procedure. Objective : to increase the accuracy of PCa diagnostics using targeted pararectal prostate biopsy guided by computed tomography (CT)/MRI. Materials and methods . A total of 95 patients underwent CT/MRI-guided targeted pararectal biopsy between March 2015 and March 2020. The mean level of prostate specific antigen (PSA) was 13.7 ± 12.6 ng/mL. All men were found to have 1 to 3 lesions with a PI-RADS score between 3 and 5. Patients were divided into 4 groups: 1 st group (n = 33) included patients in whom transrectal access was impossible; 2 nd group (n = 22) included patients with suspected local recurrence of PCa after brachytherapy; 3 rd group (n = 28) included patients with a negative result of primary biopsy, but with growing PSA level; 4th group (n = 12) included patients who preferred targeted biopsy. We performed targeted biopsy of each suspicious lesion according to MRIscans. Then we performed ‘blind’ systematic 10-14-core biopsy, where we did not take into account the location of suspicious foci and they could be, therefore, accidentally used for sample collection for the second time. Results . Histological examination revealed PCa in 71 out of 95 patients (74.7 %): in 27 out of 33 in 1 st group (81.8 %), in 19 out of 22 in 2 nd group (86.4 %), in 17 out of 28 in 3 rd group (60.7 %), and in 8 out of 12 in 4 th group (66.7 %). In 21 patients (29.6 %), PCa was diagnosed only in samples obtained using targeted biopsy; in 9 patients (12.7 %), PCa was diagnosed only in samples after systematic biopsy; in 41 patients (57.7 % PCa was detected by both targeted and systematic biopsy. Clinically significant cancer (Gleason score ≥7) was diagnosed in 84.5 % of cases after targeted biopsy and in 70.4 % of cases after systemic biopsy. Conclusion . CT/MRI-guided prostate fusion biopsy increases the accuracy of PCa diagnostics by additional detection of clinically significant tumors, including those in patients in whom the rectal access is impossible.
{"title":"Computed tomography-guided pararectal prostate fusion biopsy","authors":"A. A. Kopylov, V. Gorelov, N. Margaryants, S. Gorelov","doi":"10.17650/1726-9776-2020-16-4-89-97","DOIUrl":"https://doi.org/10.17650/1726-9776-2020-16-4-89-97","url":null,"abstract":"Background . Prostate cancer (PCa) is one of the most common malignancies. The gold standard of PCa diagnostics is morphological examination of prostate tissues obtained using 10-12-core biopsy. However, the number of false-negative results and detected clinically insignificant forms of cancer remain high. Magnetic resonance imaging (MRI) is the most sensitive and specific method of radiation diagnosis of PCa. The use of MRI data for prostate biopsy (fusion-biopsy) increases the accuracy of this procedure. Objective : to increase the accuracy of PCa diagnostics using targeted pararectal prostate biopsy guided by computed tomography (CT)/MRI. Materials and methods . A total of 95 patients underwent CT/MRI-guided targeted pararectal biopsy between March 2015 and March 2020. The mean level of prostate specific antigen (PSA) was 13.7 ± 12.6 ng/mL. All men were found to have 1 to 3 lesions with a PI-RADS score between 3 and 5. Patients were divided into 4 groups: 1 st group (n = 33) included patients in whom transrectal access was impossible; 2 nd group (n = 22) included patients with suspected local recurrence of PCa after brachytherapy; 3 rd group (n = 28) included patients with a negative result of primary biopsy, but with growing PSA level; 4th group (n = 12) included patients who preferred targeted biopsy. We performed targeted biopsy of each suspicious lesion according to MRIscans. Then we performed ‘blind’ systematic 10-14-core biopsy, where we did not take into account the location of suspicious foci and they could be, therefore, accidentally used for sample collection for the second time. Results . Histological examination revealed PCa in 71 out of 95 patients (74.7 %): in 27 out of 33 in 1 st group (81.8 %), in 19 out of 22 in 2 nd group (86.4 %), in 17 out of 28 in 3 rd group (60.7 %), and in 8 out of 12 in 4 th group (66.7 %). In 21 patients (29.6 %), PCa was diagnosed only in samples obtained using targeted biopsy; in 9 patients (12.7 %), PCa was diagnosed only in samples after systematic biopsy; in 41 patients (57.7 % PCa was detected by both targeted and systematic biopsy. Clinically significant cancer (Gleason score ≥7) was diagnosed in 84.5 % of cases after targeted biopsy and in 70.4 % of cases after systemic biopsy. Conclusion . CT/MRI-guided prostate fusion biopsy increases the accuracy of PCa diagnostics by additional detection of clinically significant tumors, including those in patients in whom the rectal access is impossible.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67764378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-10DOI: 10.17650/1726-9776-2020-16-4-17-31
N. Rubtsova, E. Kryaneva, A. B. Golbits, B. Alekseev, A. Kostin, А. Kaprin
In recent decades, due to advances in imaging and improvements in diagnostic algorithms, there has been a tendency to increase the frequency of detection of small renal masses for which nephron-sparing surgery is possible. To predict the potential complexity of partial nephrectomy and to reduce the degree of subjectivity in choosing the volume and method of surgical procedure, different groups of researchers proposed a significant number of concepts for evaluating renal tumours. The R.E.N.A.L. nephrometry score is one of the first but remains relevant and is based on a set of anatomical characteristics. This score allows to classify renal neoplasms in a structured and standardized way. This article presents a method for evaluating the parameters of R.E.N.A.L. nephrometry score, as well as a brief literature review of its prognostic significance.
{"title":"The R.E.N.A.L. nephrometry score in radiologist’s practice","authors":"N. Rubtsova, E. Kryaneva, A. B. Golbits, B. Alekseev, A. Kostin, А. Kaprin","doi":"10.17650/1726-9776-2020-16-4-17-31","DOIUrl":"https://doi.org/10.17650/1726-9776-2020-16-4-17-31","url":null,"abstract":"In recent decades, due to advances in imaging and improvements in diagnostic algorithms, there has been a tendency to increase the frequency of detection of small renal masses for which nephron-sparing surgery is possible. To predict the potential complexity of partial nephrectomy and to reduce the degree of subjectivity in choosing the volume and method of surgical procedure, different groups of researchers proposed a significant number of concepts for evaluating renal tumours. The R.E.N.A.L. nephrometry score is one of the first but remains relevant and is based on a set of anatomical characteristics. This score allows to classify renal neoplasms in a structured and standardized way. This article presents a method for evaluating the parameters of R.E.N.A.L. nephrometry score, as well as a brief literature review of its prognostic significance.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67763655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-10DOI: 10.17650/1726-9776-2020-16-4-32-38
N. Apanovich, V. I. Loginov, E. Filippova, D. S. Khodyrev, A. Burdennyy, I. Pronina, N. Ivanova, S. Lukina, T. Kazubskaya, V. Matveev, A. Karpukhin, E. Braga
methylation late (III–IV) of metastasis lymph nodes These 4 genes used to a potential metastatic prognosis system with a clinical sensitivity of 68 % and a specificity of 84 % (area under curve 0.83), which will be applied in the final development of a system for personalized therapy of RCC patients. Conclusion. The association of methylation of the MIR1258 with RCC metastasis has been shown for the first time and is of independent inter-est as a new promising marker for the prognosis of metastatic relapses.
{"title":"Methylation of a group of microRNA genes: markers of renal cell carcinoma metastasis","authors":"N. Apanovich, V. I. Loginov, E. Filippova, D. S. Khodyrev, A. Burdennyy, I. Pronina, N. Ivanova, S. Lukina, T. Kazubskaya, V. Matveev, A. Karpukhin, E. Braga","doi":"10.17650/1726-9776-2020-16-4-32-38","DOIUrl":"https://doi.org/10.17650/1726-9776-2020-16-4-32-38","url":null,"abstract":"methylation late (III–IV) of metastasis lymph nodes These 4 genes used to a potential metastatic prognosis system with a clinical sensitivity of 68 % and a specificity of 84 % (area under curve 0.83), which will be applied in the final development of a system for personalized therapy of RCC patients. Conclusion. The association of methylation of the MIR1258 with RCC metastasis has been shown for the first time and is of independent inter-est as a new promising marker for the prognosis of metastatic relapses.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67763553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-10DOI: 10.17650/1726-9776-2020-16-4-191-196
K. Nyushko, V. M. Perepukhov, B. Alekseev
Androgen deprivation therapy (ADT) is one of the main treatments for patients with locally advanced and metastatic prostate cancer. ADT decreases the level of testosterone. Despite the development of new effective drugs in recent years, luteinizing gonadotropin-releasing hormone agonists are frequently administered as ADT. One of the most commonly used first-line drugs is triptorelin (Diferelin®). In Russia, patients usually receive slow-release triptorelin administered once every month or every 3 months (intramuscular injections) and once every 3 months (subcutaneous injections); the result of using different dosage forms is comparable. Triptorelin effectively keeps serum testosterone level below 20 ng/dL, thereby increasing the time to development of castration-resistant prostate cancer, overall survival of patients receiving combination treatment with radiotherapy, and reduces the severity of symptoms from the lower urinary tract. Triptorelin has a good safety profile and is generally well tolerated by patients.
{"title":"Diferelin® as an effective chemical castration agent for patients with prostate cancer","authors":"K. Nyushko, V. M. Perepukhov, B. Alekseev","doi":"10.17650/1726-9776-2020-16-4-191-196","DOIUrl":"https://doi.org/10.17650/1726-9776-2020-16-4-191-196","url":null,"abstract":"Androgen deprivation therapy (ADT) is one of the main treatments for patients with locally advanced and metastatic prostate cancer. ADT decreases the level of testosterone. Despite the development of new effective drugs in recent years, luteinizing gonadotropin-releasing hormone agonists are frequently administered as ADT. One of the most commonly used first-line drugs is triptorelin (Diferelin®). In Russia, patients usually receive slow-release triptorelin administered once every month or every 3 months (intramuscular injections) and once every 3 months (subcutaneous injections); the result of using different dosage forms is comparable. Triptorelin effectively keeps serum testosterone level below 20 ng/dL, thereby increasing the time to development of castration-resistant prostate cancer, overall survival of patients receiving combination treatment with radiotherapy, and reduces the severity of symptoms from the lower urinary tract. Triptorelin has a good safety profile and is generally well tolerated by patients.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67763151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-10DOI: 10.17650/1726-9776-2020-16-4-48
A. Vinarov
.
．
{"title":"Review of the article “Clinical implication of kidney injury molecule (KIM-1) in blood plasma of renal-cell cancer patients”","authors":"A. Vinarov","doi":"10.17650/1726-9776-2020-16-4-48","DOIUrl":"https://doi.org/10.17650/1726-9776-2020-16-4-48","url":null,"abstract":"<jats:p>.</jats:p>","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67764622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-10DOI: 10.17650/1726-9776-2020-16-4-170-171
O. V. Mukhortova
.
．
{"title":"Review of the article «18 F-FDG positron emission tomography combined with computed tomography in renal cell carcinoma diagnostics»","authors":"O. V. Mukhortova","doi":"10.17650/1726-9776-2020-16-4-170-171","DOIUrl":"https://doi.org/10.17650/1726-9776-2020-16-4-170-171","url":null,"abstract":"<jats:p>.</jats:p>","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"32 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67763259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-09DOI: 10.17650/1726-9776-2020-16-4-61-81
Enrique Grande, Н. Glen, J. Aller, G. Argenziano, M. J. Lamas, P. Ruszniewski, J. Zamorano, K. Edmonds, S. Sarker, Michael Staehler, J. Larkin
.
．
{"title":"Рекомендации по лечению пациентов с прогрессирующим или метастатическим почечно-клеточным раком комбинацией ленватиниба и эверолимуса","authors":"Enrique Grande, Н. Glen, J. Aller, G. Argenziano, M. J. Lamas, P. Ruszniewski, J. Zamorano, K. Edmonds, S. Sarker, Michael Staehler, J. Larkin","doi":"10.17650/1726-9776-2020-16-4-61-81","DOIUrl":"https://doi.org/10.17650/1726-9776-2020-16-4-61-81","url":null,"abstract":"<jats:p>.</jats:p>","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"16 1","pages":"61-81"},"PeriodicalIF":0.1,"publicationDate":"2021-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67764282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-11-19DOI: 10.17650/1726-9776-2020-16-3-174-189
E. Yakubovich, A. G. Polishchuk, V. I. Evtushenko
Early diagnosis of renal cancer carcinoma is a key determinant of patient survival. The asymptomatic disease course and lack of reliable diagnostic markers lead to the fact that more than 30 % renal cancer cases discovered at an advanced stage, when the prognosis is poor because kidney tumors are resistant to standard chemotherapy and radiation. More than 30 % of renal cancer carcinoma recur or metastasize after surgical treatment. Despite the implementation of novel targeted drugs and immune point inhibitors, the 5-year survival rate for metastatic renal cancer carcinoma remains dismal. Unsatisfactory result of renal cancer treatment may be caused by high inter- and intra-tumor heterogeneity and tumor evolution during therapy, as well as the lack of predictive and on-treatment monitoring biomarkers. Liquid biopsy test that utilizes free-circulating DNA (cfDNA) in the blood of patients, opens up new opportunities for managing patients with renal cancer. The diagnostic and predictive potential of these minimally invasive biomarkers has been demonstrated for various types of cancer. The use of highly sensitive methods of cfDNA analysis may allow early cancer detection and prediction of postoperative disease recurrence before dinical and radiographic progression. Serial cfDNA samples, that were collected before and during course of treatment, can provide information about the dynamic mutational changes in the volume of the entire tumor and metastases in real time, and the emergence of drug resistance during treatment. This information may be promising toolfor optimizing patient-specific therapeutic strategies. This review is focusing on the potential clinical application of cfDNA from blood in renal cancer.
{"title":"Potential clinical application of free-circulating DNA from blood in renal cancer","authors":"E. Yakubovich, A. G. Polishchuk, V. I. Evtushenko","doi":"10.17650/1726-9776-2020-16-3-174-189","DOIUrl":"https://doi.org/10.17650/1726-9776-2020-16-3-174-189","url":null,"abstract":"Early diagnosis of renal cancer carcinoma is a key determinant of patient survival. The asymptomatic disease course and lack of reliable diagnostic markers lead to the fact that more than 30 % renal cancer cases discovered at an advanced stage, when the prognosis is poor because kidney tumors are resistant to standard chemotherapy and radiation. More than 30 % of renal cancer carcinoma recur or metastasize after surgical treatment. Despite the implementation of novel targeted drugs and immune point inhibitors, the 5-year survival rate for metastatic renal cancer carcinoma remains dismal. Unsatisfactory result of renal cancer treatment may be caused by high inter- and intra-tumor heterogeneity and tumor evolution during therapy, as well as the lack of predictive and on-treatment monitoring biomarkers. Liquid biopsy test that utilizes free-circulating DNA (cfDNA) in the blood of patients, opens up new opportunities for managing patients with renal cancer. The diagnostic and predictive potential of these minimally invasive biomarkers has been demonstrated for various types of cancer. The use of highly sensitive methods of cfDNA analysis may allow early cancer detection and prediction of postoperative disease recurrence before dinical and radiographic progression. Serial cfDNA samples, that were collected before and during course of treatment, can provide information about the dynamic mutational changes in the volume of the entire tumor and metastases in real time, and the emergence of drug resistance during treatment. This information may be promising toolfor optimizing patient-specific therapeutic strategies. This review is focusing on the potential clinical application of cfDNA from blood in renal cancer. ","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2020-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67761727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：